The biopharma company Amarin might be winning hearts (and saving them) with its formulation of fish oil, called Vascepa.
Potentially mitigating skepticism surrounding the long-term benefits of omega-3 fatty acids, tests conducted by Amarin support Vascepa’s potential. Named REDUCE-IT, the company’s cardiovascular outcomes study revealed that Vascepa could reduce cardiovascular risks (such as heart attacks and strokes) by a significant 25%. The results could potentially hail Amarin’s Vascepa as a sought-after cardiovascular therapy for Americans, which makes one wonder if the stock price could follow.